|Day's Range||31.23 - 31.36|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||21.50|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.
Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia from the U.S. Food and Drug Administration, the Swiss drugmaker said on Friday. The designation covers Venclexta ...
AstraZeneca topped profit views, but shares crashed on an immuno-oncology setback. Roche also beat.